Amgen (AMGN) Announces Early Submission Conclusion for CODEBREAK100 with No Supporting Data; Investors Confused - Piper Sandler
Tweet Send to a Friend
Piper Sandler analyst Christopher Raymond reiterated an Overweight rating and $270.00 price target on Amgen (NASDAQ: AMGN) after the company ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
